Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors

키워드

참고문헌 (119)

1. Goodfellow PN, "SRY and sex determination in mammals", Annu Rev Genet, 27, pp.71~92 (1993)
2. Jost A, "Recherches sur la differenciation sexuelle de l’embryon de lapin", Arch Anat Microsc Morphol Exp, 36, pp.271~315 (1947)
3. Jost A, "Problems of fetal endocrinology: the gonadal and hypophyseal hormones", Rec Prog Horm Res, 8, pp.379~418 (1953)
4. Price JM, "Programmed cell death in the Mullerian duct induced by Mullerian inhibiting substance", Am J Anat, 149, pp.353~375 (1977)
5. Price JM, "Involution of the female Mullerian duct of the fetal rat in the organ-culture assay for the detection of Mullerian Inhibiting Substance", Am J Anat, 156, pp.265~284 (1979)
6. Hayashi A, "Periductal and matrix glycosaminoglycans in rat Mullerian duct development and regression", Dev Biol, 92, pp.16~26 (1982)
7. Trelstad RL, "The epithelial-mesenchymal interface of the male rate Mullerian duct: loss of basement membrane integrity and ductal regression", Dev Biol, 92, pp.27~40 (1982)
8. Ikawa H, "Changing patterns of fibronectin, laminin, type IV collagen, and a basement membrane proteoglycan during rat Mullerian duct regression", Dev Biol, 102, pp.260~263 (1984)
9. Dyche WJ, "A comparative study of the differentiation and involution of the Mullerian duct and Wolffian duct in the male and female fetal mouse", J Morphol, 162, pp.175~209 (1979)
10. Josso N, "In vitro synthesis of mullerian-inhibiting hormone by seminiferous tubules isolated from the calf fetal testis", Endocrinology, 93, pp.829~834 (1973)
11. Blanchard MG, "Source of the anti-Mullerian hormone synthesized by the fetal testis: Mullerian-inhibiting activity of fetal bovine Sertoli cells in tissue culture", Pediatr Res, 8, pp.968~971 (1974)
12. Picon R, "Action of the fetal testis on the development in vitro of the Mullerian ducts in the rat", Arch Anat Microsc Morphol Exp, 58, pp.1~19 (1969)
13. Josso N, "Mullerian-inhibiting activity of calf fetal testes: relationship to testosterone and protein synthesis", Biol Reprod, 13, pp.163~167 (1975)
14. Donahoe PK, "Mullerian inhibiting substance activity in bovine fetal, newborn and prepubertal testes", Biol Reprod, 16, pp.238~243 (1977)
15. Josso N, "Permeability of membranes to the Mullerian-inhibiting substance synthesized by the human fetal testis in vitro: a clue to its biochemical nature", J Clin Endocrinol Metab, 34, pp.265~270 (1972)
16. Donahoe PK, "Mullerian inhibiting substance in human testes after birth", J Pediatr Surg, 12, pp.323~330 (1977)
17. Shen WH, "Nuclear receptor steroidogenic factor 1 regulates the mullerian inhibiting substance gene: a link to the sex determination cascade", Cell, 77, pp.651~661 (1994)
18. Giuili G, "The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian Inhibiting Substance, in vivo", Development, 124, pp.1799~1807 (1997)
19. Arango NA, "Targeted mutagenesis of the endogenous mouse Mis gene promoter:in vivo definition of genetic pathways of vertebrate sexual development", Cell, 99, pp.409~419 (1999)
20. Hossain A, "Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Mullerian-inhibiting substance promoter", Biol Reprod, 69, pp.1808~1814 (2003)
21. Nachtigal MW, "Wilms’ tumor 1and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression", Cell, 93, pp.445~454 (1998)
22. Tremblay JJ, "Nuclear receptor Dax-1 represses the transcriptional cooperation between GATA-4 and SF-1 in Sertoli cells", Biol Reprod, 64, pp.1191~1199 (2001)
23. Lasala C, "Subcellular and molecular mechanisms regulating anti-Mullerian hormone gene expression in mammalian and nonmammalian species", DNA Cell Biol, 23, pp.572~585 (2004)
24. Teixeira J, "Mullerian-inhibiting substance regulates androgen synthesis at the transcriptional level", Endocrinology, 140, pp.4732~4738 (1999)
25. Laurich VM, "Mullerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase", C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation, 2002, pp.143, 3351~3360
26. Sriraman V, "Mullerian inhibiting substance inhibits testosterone synthesis in adult rats", J Androl, 22, pp.750~758 (2001)
27. Bezard J, "Immunocytochemical study of anti-Mullerian hormone in sheep ovarian follicles during fetal and post-natal development", J Reprod Fertil, 80, pp.509~516 (1987)
28. MacLaughlin DT, "Mullerian inhibiting substance", anti-Mullerian hormone: a potential therapeutic agent for human ovarian and other cancers, 2010, pp.6, 391~405
29. Hudson PL, "An immunoassay to detect human mullerian inhibiting substance in males and females during normal development", J Clin Endocrinol Metab, 70, pp.16~22 (1990)
30. Josso N, "An enzyme linked immunoassay for anti-mullerian hormone: a new tool for the evaluation of testicular function in infants and children", J Clin Endocrinol Metab, 70, pp.23~27 (1990)
31. Baker ML, "Serum levels of mullerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay", J Clin Endocrinol Metab, 70, pp.11~15 (1990)
32. Ueno S, "Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro", Endocrinology, 123, pp.1652~1659 (1988)
33. Kim JH, "The inhibitory effects of mullerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells", J Clin Endocrinol Metab, 75, pp.911~917 (1992)
34. Durlinger AL, "Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary", Endocrinology, 140, pp.5789~5796 (1999)
35. Seifer DB, "Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid mullerian-inhibiting substance and androgen content", J Clin Endocrinol Metab, 76, pp.711~714 (1993)
36. Seifer DB, "Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles", Fertil Steril, 77, pp.468~471 (2002)
37. Trbovich AM, "Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents", Proc Natl Acad Sci U S A, 98, pp.3393~3397 (2001)
38. Lee MM, "Mullerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells", Endocrinology, 140, pp.2819~2827 (1999)
39. Baarends WM, "Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat", Endocrinology, 136, pp.5614~5622 (1995)
40. Bedecarrats GY, "Regulation of gonadotropin gene expression by Mullerian inhibiting substance", Proc Natl Acad Sci U S A, 100, pp.9348~9353 (2003)
41. Wang PY, "Mullerian inhibiting substance acts as a motor neuron survival factor in vitro", Proc Natl Acad Sci U S A, 102, pp.16421~16425 (2005)
42. Segev DL, "Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo", Proc Natl Acad Sci U S A, 99, pp.239~244 (2002)
43. Hoshiya Y, "Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells", Mol Cell Endocrinol, 211, pp.43~49 (2003)
44. Segev DL, "Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo", J Biol Chem, 276, pp.26799~26806 (2001)
45. Hoshiya Y, "Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells", J Biol Chem, 278, pp.51703~51712 (2003)
46. Gupta V, "Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model", Proc Natl Acad Sci U S A, 102, pp.3219~3224 (2005)
47. Parry RL, "Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo", Cancer Res, 52, pp.1182~1186 (1992)
48. Vigier B, "A monoclonal antibody against bovine anti-Mullerian hormone", Endocrinology, 110, pp.131~137 (1982)
49. Shima H, "Production of monoclonal antibodies for affinity purification of bovine mullerian inhibiting substance activity", Hybridoma, 3, pp.201~214 (1984)
50. Picard JY, "Anti-Mullerian hormone: estimation of molecular weight by gel filtration", Biomedicine, 25, pp.147~150 (1976)
51. Picard JY, "Purification of testicular anti-Mullerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor", Mol Cell Endocrinol, 34, pp.23~29 (1984)
52. Swann DA, "Extraction of Mullerian inhibiting substance from newborn calf testis", Dev Biol, 69, pp.73~84 (1979)
53. Budzik GP, "Enhanced purification of Mullerian inhibiting substance by lectin affinity chromatography", Cell, 21, pp.909~915 (1980)
54. Budzik GP, "Mullerian inhibiting substance fractionation by dye affinity chromatography", Cell, 34, pp.307~314 (1983)
55. Cate RL, "Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells", Cell, 45, pp.685~698 (1986)
56. Picard JY, "Cloning and expression of cDNA for anti-mullerian hormone", Proc Natl Acad Sci U S A, 83, pp.5464~5468 (1986)
57. Cohen-Haguenauer O, "Mapping of the gene for anti-mullerian hormone to the short arm of human chromosome 19", Cytogenet Cell Genet, 44, pp.2~6 (1987)
58. Pepinsky RB, "Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment", J Biol Chem, 263, pp.18961~18964 (1988)
59. MacLaughlin DT, "Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain", Endocrinology, 131, pp.291~296 (1992)
60. Wilson CA, "Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily", Mol Endocrinol, 7, pp.247~257 (1993)
61. Ragin RC, "Human mullerian inhibiting substance:enhanced purification imparts biochemical stability and restores antiproliferative effects", Protein Expr Purif, 3, pp.236~245 (1992)
62. Lorenzo HK, "New approaches for high-yield purification of Mullerian inhibiting substance improve its bioactivity", J Chromatogr B Analyt Technol Biomed Life Sci, 766, pp.89~98 (2002)
63. Baarends WM, "A novel member of the transmembrane serine", threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct, 1994, pp.120, 189~197
64. Di Clemente N, "Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone", Mol Endocrinol, 8, pp.1006~1020 (1994)
65. Teixeira J, "Developmental expression of a candidate mullerian inhibiting substance type II receptor", Endocrinology, 137, pp.160~165 (1996)
66. Mishina Y, "Sequence, genomic organization, and chromosomal location of the mouse Mullerian-inhibiting substance type II receptor gene", Biochem Biophys Res Commun, 237, pp.741~746 (1997)
67. Imbeaud S, "Insensitivity to anti-mullerian hormone due to a mutation in the human anti-mullerian hormone receptor", Nat Genet, 11, pp.382~388 (1995)
68. Racine C, "Receptors for anti-mullerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation", Proc Natl Acad Sci U S A, 95, pp.594~599 (1998)
69. Baarends WM, "Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth", Endocrinology, 136, pp.4951~4962 (1995)
70. Renaud EJ, "Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance", Proc Natl Acad Sci U S A, 102, pp.111~116 (2005)
71. Josso N, "AMH and AMH receptor defects in persistent Mullerian duct syndrome", Hum Reprod Update, 11, pp.351~356 (2005)
72. Hoshiya M, "Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene", Birth Defects Res A Clin Mol Teratol, 67, pp.868~874 (2003)
73. Gouedard L, "Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor", J Biol Chem, 275, pp.27973~27978 (2000)
74. Visser JA, "The serine", threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling, 2001, pp.15, 936~945
75. Jamin SP, "Requirement of Bmpr1a for Mullerian duct regression during male sexual development", Nat Genet, 32, pp.408~410 (2002)
76. He WW, "Developmental expression of four novel serine", threonine kinase receptors homologous to the activin, Dev Dyn, pp.1993, 196[DOI]
77. Clarke TR, "Mullerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression", Mol Endocrinol, 15, pp.946~959 (2001)
78. Gu Z, "The type I serine", threonine kinase receptor ActRIA (ALK2)is required for gastrulation of the mouse embryo, 1999, pp.126, 2551~2561
79. Lee MM, "Measurements of serum mullerian inhibiting substance in the evaluation of children with nonpalpable gonads", N Engl J Med, 336, pp.1480~1486 (1997)
80. Van Rooij IA, "Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve", Hum Reprod, 17, pp.3065~3071 (2002)
81. Muttukrishna S, "Inhibin B and anti-Mullerian hormone:markers of ovarian response in IVF", ICSI patients?, 2004, pp.111, 1248~1253
82. Hazout A, "Serum antimullerian hormone", mullerianinhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol, 2004, pp.82, 1323~1329
83. Penarrubia J, "Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropinreleasing hormone agonist: gonadotropin treatment", Hum Reprod, 20, pp.915~922 (2005)
84. Eldar-Geva T, "Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome", Hum Reprod, 20, pp.3178~3183 (2005)
85. Silberstein T, "Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology", Hum Reprod, 21, pp.159~163 (2006)
86. Gustafson ML, "Mullerian inhibiting substance as a marker for ovarian sex-cord tumor", N Engl J Med, 326, pp.466~471 (1992)
87. Gustafson ML, "Mullerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities", J Pediatr Surg, 28, pp.439~444 (1993)
88. Chang HL, "Serum Mullerian Inhibiting Substance", anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology, 2009, pp.114, 57~60
89. Dutertre M, "Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice", Endocrinology, 142, pp.4040~4046 (2001)
90. Donahoe PK, "Enhanced purification and production of Mullerian inhibiting substance for therapeutic applications", Mol Cell Endocrinol, 211, pp.37~42 (2003)
91. Teixeira J, "Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications", Endocr Rev, 22, pp.657~674 (2001)
92. Di Clemente N, "Components of the anti-Mullerian hormone signaling pathway in gonads", Mol Cell Endocrinol, 211, pp.9~14 (2003)
93. Josso N, "Transduction pathway of anti-Mullerian hormone, a sex-specific member of the TGFbeta family", Trends Endocrinol Metab, 14, pp.91~97 (2003)
94. Scully RE, "Recent progress in ovarian cancer", Hum Pathol, 1, pp.73~98 (1970)
95. Donahoe PK, "Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer", Science, 205, pp.913~915 (1979)
96. Fuller AF Jr, "Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line", J Clin Endocrinol Metab, 54, pp.1051~1055 (1982)
97. Masiakos PT, "Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS", Clin Cancer Res, 5, pp.3488~3499 (1999)
98. Stephen AE, "Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo", Clin Cancer Res, 8, pp.2640~2646 (2002)
99. Berkenblit A, "Advances in the management of epithelial ovarian cancer", J Reprod Med, 50, pp.426~438 (2005)
100. Barbie TU, "Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130and p107", Proc Natl Acad Sci U S A, 100, pp.15601~15606 (2003)
101. Jemal A, "Cancer statistics, 2003", CA Cancer J Clin, 53, pp.5~26 (2003)
102. Salom E, "Management of recurrent ovarian cancer: evidence-based decisions", Curr Opin Oncol, 14, pp.519~527 (2002)
103. Donahoe PK, "Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice", Ann Surg, 194, pp.472~480 (1981)
104. Chin TW, "Human mullerian inhibiting substance inhibits tumor growth in vitro and in vivo", Cancer Res, 51, pp.2101~2106 (1991)
105. Ha TU, "Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism", J Biol Chem, 275, pp.37101~37109 (2000)
106. Fuller AF Jr, "Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay", Gynecol Oncol, 22, pp.135~148 (1985)
107. Bakkum-Gamez JN, "Mullerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers", Gynecol Oncol, 108, pp.141~148 (2008)
108. Song JY, "The expression of Mullerian inhibiting substance", anti-Mullerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia, 2009, pp.34, 1583~1591
109. Connolly DC, "Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer", Cancer Res, 63, pp.1389~1397 (2003)
110. Pieretti-Vanmarcke R, "Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo", Clin Cancer Res, 12, pp.1593~1598 (2006)
111. MacLaughlin DT, "in cancer therapy", pp.333~354 (2008), Humana Press
112. Nam SW, "Identification of large-scale characteristic genes of Mullerian inhibiting substance in human ovarian cancer cells", Int J Mol Med, 23, pp.589~596 (2009)
113. Pieretti-Vanmarcke R, "Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer", Proc Natl Acad Sci U S A, 103, pp.17426~17431 (2006)
114. Song JY, "Expression of Mullerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer", Int J Oncol, 40, pp.2013~2021 (2012)
115. Hwang SJ, "Identification of characteristic molecular signature of Mullerian inhibiting substance in human HPV-related cervical cancer cells", Int J Oncol, 39, pp.811~820 (2011)
116. Sovak MA, "Aberrant nuclear factor-kappaB", Rel expression and the pathogenesis of breast cancer, 1997, pp.100, 2952~2960
117. Nakshatri H, "Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth", Mol Cell Biol, 17, pp.3629~3639 (1997)
118. Namkung J, "Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis", J Clin Endocrinol Metab, 97, pp.3224~3230 (2012)
119. Borahay MA, "Mullerian inhibiting substance suppresses proliferation and induces apoptosis and autophagy in endometriosis cells in vitro", ISRN Obstet Gynecol, 2013, pp.361489~ (2013)

관련 논문AI추천